CTI BioPharma (CTIC) Misses Q4 EPS by 4c

CTI BioPharma (NASDAQ: CTIC) reported Q4 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16).

"This past quarter, CTI has executed on the critical clinical, regulatory and commercial activities that will allow for the potential U.S. approval and commercial launch of pacritinib in 2021," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "We continue to work diligently on our rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for pacritinib, for use in myelofibrosis patients with severe thrombocytopenia, and are on track to complete the submission before the end of this month. Pending priority review and approval by the FDA, we are planning to launch pacritinib in the United States by the end of the year. Over the last quarter, we have focused on the key pre-commercial activities that will enable a successful launch, including the recruitment of key leadership roles in marketing and sales, and the initiation of our disease awareness, market access, and field force strategies. We look forward to being able to provide pacritinib to myelofibrosis patients who are underserved by existing therapies."

For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Optimum Communications gets NYSE non-compliance notice over stock price